ADHERENCE TO THE TREATMENT OF ISCHEMIC HEART DISEASE

Abstract

The factors associated with poor adherence to the treatment of ischemic heart disease in patients of a public hospital in Guayaquil, Ecuador in the 2017 period were analyzed. This is a descriptive, observational cross-sectional study. The sample was 119 patients, the SPSS version 21 software was used to analyze the information. Being more frequent in the male sex (62%), middle adults and older adults with 50% and 47% respectively. The most frequent ischemic heart disease variety was stable angina pectoris with 67% (80. Statistically significant association was demonstrated between the degree of adherence to treatment with the presence of risk factors (p = 0.000), which increases six times the risk of non-adherence to treatment in relation to the group that does not have them (OR: 6.484).). The main risk factors associated with non-adherence to treatment were the age over 60 years and the difficulty in obtaining a medical appointment with 97%. The risk factors have a negative influence on the poor adherence of the treatment, so it requires speed in the subsequent consultation controls.

Keywords: Poor adhesion, ischemic heart disease, angina pectoris.

References

[1]OPS (2018). “Una atencion limpia y segura”, [Online] Available from:  https://www.who.int/gpsc/country_work/burden_hcai/es/ [Last access: 2019]

[2]D. Kasper, A. Fauci, S. Hauser, D. Longo, J. Jameson and J. Loscalzo, “Principios de Medicina Interna", Cap. 67: Cradiopatía isquémica. 19ª edition. (McGraw-Hill), 2016.

[3]M.Crawford, J. DiMarco and W. Paulus, “Cardiology. Chapter 71: Ischemic cardiopathy”. 3d edition. Elsevier, 2013.

[4] D. Mann. “Braunwald’s Heart Disease Practice Guidelines”, Chapter 22: Ischemic cardiopathy. 1st Edition. Elsevier, 2016.

[5]A. Armitage, C. Drazen, G. Landry and R. Scheld, "Goldman´s Cecil Medicine”. Seccion 15. Cap. 70: Cardiopatía isquémica. 25ª edition. Vol. 2. 2 vols. Elsevier, 2015.

[6] A. Afzal, (2019), "Impact of Renal Dysfunction on Periprocedural Outcomes in Patients with Ischemic Cardiomyopathy Undergoing Elective Percutaneous Coronary Intervention (PCI)", [Online] Available from:  https://www.onlinejcf.com: https://www.onlinejcf.com/article/S1071-9164(19)31140-6/fulltext [Last access: 2019]

[7]D. Mori, et. al. (2019), "Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype", [Online] Available from:  https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0829-x [Last access: 2019]

[8] R. amamoto, et. al. (2019), "Long-term outcome of ischemic cardiomyopathy after autologous myoblast cell-sheet implantation", [Online] Available from:  https://www.sciencedirect.com/science/article/pii/S0003497519305090 [Last access: 2019]

[9] S. Shyam, et. al. (2019 ), "Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy", [Online] Available from:  https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.118.036065 [[Last access: 2019]

[10] J. Wang, et. al. (2019). "P312 Quantitative imaging biomarkers of cardiac sympathetic innervation and perfusion using C-11-meta-hydroxyephedrine and N-13-ammonia PET in ischemic cardiomyopathy", [Online] Available from:  https://academic.oup.com/ehjcimaging/article/20/Supplement_3/jez148.040/5512859 [Last access: 2019]